Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first
OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration …

Solid cancers comprise a large number of new cases and deaths from cancer each year
globally. There are a number of strategies for addressing tumors raised from solid organs …

Oncolytic adenovirus therapy is gaining importance as a novel treatment option for the
management of various cancers. Different concepts of modification within the adenovirus …

Cancer cell death is the utmost aim in cancer therapy. Anti-cancer agents can induce
apoptosis, mitotic catastrophe, senescence, or autophagy through the production of free …

Background Until recently, patients who have the same type and stage of cancer all receive
the same treatment. It has been established, however, that individuals with the same …

Abstract Interleukin-6 (IL-6) is a multi-tasking cytokine that represents high activity in patients
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. High …

Hypoxia is a known feature of solid tumors and a critical promoter of tumor hallmarks.
Hypoxia influences tumor immunity in a way favoring immune evasion and resistance …

Viruses as cancer therapies have attracted attention since the 19th century. Scientists
observation that viruses can preferentially lyse cancer cells rather than healthy cells, created …

Macrophages are the most abundant and one of the most critical cells of tumor immunity.
They provide a bridge between innate and adaptive immunity through releasing cytokines …

Abstract Oncolytic adenoviruses (OAds), engineered Ads preferentially infect and lyse tumor
cells, have attracted remarkable attention as immunotherapy weapons for the treatment of …